Novavax Files Definitive Proxy Statement
Ticker: NVAX · Form: DEFA14A · Filed: Apr 27, 2026 · CIK: 0001000694
| Field | Detail |
|---|---|
| Company | Novavax Inc (NVAX) |
| Form Type | DEFA14A |
| Filed Date | Apr 27, 2026 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-filing, regulatory, shareholder-meeting
TL;DR
NOVAVAX filed proxy docs 4/27/26 - shareholder votes coming up.
AI Summary
Novavax Inc. filed a Definitive Proxy Statement (DEFA14A) on April 27, 2026. This filing is related to soliciting materials for shareholder voting. The company's principal executive offices are located at 21 Firstfield Road, Gaithersburg, MD.
Why It Matters
This filing indicates that Novavax is proceeding with shareholder votes, which could impact corporate governance and future strategic decisions.
Risk Assessment
Risk Level: low — A DEFA14A filing is a standard regulatory document for shareholder meetings and does not inherently signal increased risk.
Key Players & Entities
- NOVAVAX INC (company) — Filer
- 21 FIRSTFIELD RD GAITHERSBURG MD (company) — Business Address
FAQ
What is the purpose of a DEFA14A filing?
A DEFA14A filing is used to provide definitive proxy soliciting materials to shareholders for voting on company matters.
When was this DEFA14A filing accepted by the SEC?
This DEFA14A filing was accepted on April 27, 2026.
What is Novavax Inc.'s CIK number?
Novavax Inc.'s CIK number is 0001000694.
What is Novavax Inc.'s SIC code and industry classification?
Novavax Inc.'s SIC code is 2836, classified under Biological Products, (No Diagnostic Substances).
Where are Novavax Inc.'s principal executive offices located?
Novavax Inc.'s principal executive offices are located at 21 Firstfield Road, Gaithersburg, MD.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 27, 2026 regarding NOVAVAX INC (NVAX).